Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorDr. Waseem Ullah

About this trial

Laryngoscopy and intubation during laparoscopic cholecystectomy often cause sudden increases in heart rate and blood pressure, which can be harmful in some patients. Medications such as labetalol and lignocaine are commonly used to reduce this hemodynamic response. This randomized controlled trial at Hayatabad Medical Complex, Peshawar, will compare intravenous labetalol (0.25 mg/kg) and lignocaine (1.5 mg/kg), administered 3 minutes before laryngoscopy. A total of 116 patients undergoing elective laparoscopic cholecystectomy will be randomly assigned to either drug group. The primary goal is to determine which drug is more effective in keeping heart rate and mean arterial pressure within ±20% of baseline during and after intubation. The study will also record blood pressure trends, intubation details, rescue medications, and adverse events such as bradycardia or hypotension. Results will help guide anesthesiologists in selecting the safer and more effective option to maintain cardiovascular stability during surgery.

Eligibility criteria

Qualifiers

ASA Grade I and II

Age 18 to 60 years

Elective laparoscopic cholecystectomy

Both genders

Disqualifiers

Hypersensitivity to labetalol/lignocaine

Hypertensive on antihypertensives

ASA Grade III or more

Cardiovascular, renal, hepatic, or endocrine issues

Trial design

Treatments tested in this trial

  • Labetalol
  • Lignocaine

Treatment groups

116 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Dr. Waseem Ullah

Lead sponsor

Lady Reading Hospital, Pakistan

Sponsor institution

Hayatabad Medical Complex

Collaborator